Hemoperfusion effect in treatment of patients with COVID-19

Not Applicable

Recruiting

Conditions: The effect of Hemoperfusion in the treatment of covid-19 disease.
COVID-19, virus identified
U07.1

Registration Number: IRCT20110425006280N12

Lead Sponsor: Vice President of Research Guilan university of medical sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 20

Inclusion Criteria

Patients with a clinical diagnosis of Covid-19 including respiratory distress with a rate of more than 30 per minute and heart rate more than 125 beats per minute and shortness of breath and oxygen saturation less than 90%, despite receiving oxygen with a positive PCR test and Radiographs in CT SCANING or Chest X Ray, admitted to the intensive care unit.
Uncontrollable fevers like T> 39 C.
An laboratory evidence of increased inflammatory factors
Patients 12 years and older
Evidence of severe hemodynamic disturbance using moderate doses of norepinephrine or using a second dose of vasopressor
Involvement of more than two vital organs (lungs, kidneys, liver, and heart)

Exclusion Criteria

Thrombocytopenia (Plt =20,000)
Pregnancy
Acute crisis due to sickle cell anemia
Evidence of resin sensitivity

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improving the patient's clinical condition. Timepoint: Daily. Method of measurement: Evaluation of the presence of Respiratory distress, marked improvement in patients respiration rate, improvement in arterial blood gas condition and self-expression, improvement in patient's heart rate and improvement in patient's inflammatory tests 2-3 days after home perfusion. Inflammatory tests include D.DIMER, IL-6 LDH, FERRITIN, FIBRINOGEN, CRP.

Secondary Outcome Measures